Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 16 studies | 33% ± 18% | |
peripheral blood | 13 studies | 22% ± 7% | |
lung | 10 studies | 24% ± 8% | |
adipose | 4 studies | 21% ± 4% | |
bone marrow | 3 studies | 19% ± 3% | |
kidney | 3 studies | 18% ± 1% | |
liver | 3 studies | 25% ± 9% | |
intestine | 3 studies | 20% ± 4% | |
skin | 3 studies | 19% ± 1% | |
lymph node | 3 studies | 17% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
bladder | 100% | 3593.33 | 21 / 21 | 100% | 60.60 | 504 / 504 |
esophagus | 100% | 4392.01 | 1445 / 1445 | 100% | 74.97 | 183 / 183 |
lung | 100% | 4060.14 | 578 / 578 | 100% | 69.58 | 1155 / 1155 |
ovary | 100% | 3115.39 | 180 / 180 | 100% | 51.24 | 430 / 430 |
stomach | 100% | 2578.85 | 359 / 359 | 100% | 60.23 | 286 / 286 |
brain | 100% | 4100.06 | 2641 / 2642 | 100% | 88.34 | 705 / 705 |
breast | 100% | 4029.71 | 459 / 459 | 100% | 68.80 | 1116 / 1118 |
intestine | 100% | 3604.90 | 966 / 966 | 100% | 62.14 | 526 / 527 |
prostate | 100% | 3153.38 | 245 / 245 | 100% | 46.11 | 500 / 502 |
uterus | 100% | 3320.73 | 170 / 170 | 100% | 64.95 | 457 / 459 |
thymus | 100% | 3017.52 | 653 / 653 | 99% | 49.60 | 600 / 605 |
pancreas | 99% | 1812.34 | 325 / 328 | 99% | 57.87 | 176 / 178 |
kidney | 100% | 2863.91 | 89 / 89 | 98% | 42.27 | 881 / 901 |
skin | 100% | 5466.18 | 1809 / 1809 | 97% | 50.36 | 456 / 472 |
liver | 100% | 1636.12 | 226 / 226 | 93% | 29.19 | 378 / 406 |
adrenal gland | 100% | 2060.99 | 257 / 258 | 90% | 21.88 | 208 / 230 |
adipose | 100% | 3926.92 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3873.55 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 92.20 | 29 / 29 |
spleen | 100% | 4020.87 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 73.59 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 20.11 | 1 / 1 |
muscle | 99% | 1628.22 | 794 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 4905.85 | 915 / 929 | 0% | 0 | 0 / 0 |
heart | 95% | 1532.77 | 815 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 94% | 41.94 | 75 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0072673 | Biological process | lamellipodium morphogenesis |
GO_0007169 | Biological process | cell surface receptor protein tyrosine kinase signaling pathway |
GO_0048813 | Biological process | dendrite morphogenesis |
GO_0001764 | Biological process | neuron migration |
GO_0008154 | Biological process | actin polymerization or depolymerization |
GO_0035855 | Biological process | megakaryocyte development |
GO_0001756 | Biological process | somitogenesis |
GO_0061098 | Biological process | positive regulation of protein tyrosine kinase activity |
GO_0098858 | Cellular component | actin-based cell projection |
GO_0005856 | Cellular component | cytoskeleton |
GO_0032433 | Cellular component | filopodium tip |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005829 | Cellular component | cytosol |
GO_0014069 | Cellular component | postsynaptic density |
GO_0030426 | Cellular component | growth cone |
GO_0030027 | Cellular component | lamellipodium |
GO_0031209 | Cellular component | SCAR complex |
GO_0005634 | Cellular component | nucleus |
GO_0045296 | Molecular function | cadherin binding |
GO_0030296 | Molecular function | protein tyrosine kinase activator activity |
GO_0035591 | Molecular function | signaling adaptor activity |
GO_0008092 | Molecular function | cytoskeletal protein binding |
GO_0005515 | Molecular function | protein binding |
GO_0017124 | Molecular function | SH3 domain binding |
Gene name | ABI1 |
Protein name | Abl interactor 1 (Abl-interactor 1 variant 21) Alternative protein ABI1 Abl interactor 1 Abl interactor 1 (Abelson interactor 1) (Abi-1) (Abl-binding protein 4) (AblBP4) (Eps8 SH3 domain-binding protein) (Eps8-binding protein) (Nap1-binding protein) (Nap1BP) (Spectrin SH3 domain-binding protein 1) (e3B1) |
Synonyms | SSH3BP1 |
Description | FUNCTION: May act in negative regulation of cell growth and transformation by interacting with nonreceptor tyrosine kinases ABL1 and/or ABL2. May play a role in regulation of EGF-induced Erk pathway activation. Involved in cytoskeletal reorganization and EGFR signaling. Together with EPS8 participates in transduction of signals from Ras to Rac. In vitro, a trimeric complex of ABI1, EPS8 and SOS1 exhibits Rac specific guanine nucleotide exchange factor (GEF) activity and ABI1 seems to act as an adapter in the complex. Regulates ABL1/c-Abl-mediated phosphorylation of ENAH. Recruits WASF1 to lamellipodia and there seems to regulate WASF1 protein level. In brain, seems to regulate the dendritic outgrowth and branching as well as to determine the shape and number of synaptic contacts of developing neurons. . |
Accessions | ENST00000490841.7 [Q8IZP0-11] ENST00000376139.6 [Q8IZP0-5] ENST00000376170.8 [Q8IZP0-4] ENST00000536334.5 ENST00000359188.8 [Q8IZP0-6] L8EC66 B6VEX4 ENST00000376138.7 [Q8IZP0-3] A0A0A0MRT6 ENST00000376160.5 ENST00000376166.5 [Q8IZP0-2] Q8IZP0 ENST00000376137.9 [Q8IZP0-7] ENST00000376140.4 [Q8IZP0-9] ENST00000376142.6 [Q8IZP0-1] ENST00000346832.10 [Q8IZP0-12] |